View Future GrowthPangaea Oncology 過去の業績過去 基準チェック /06Pangaea Oncologyの収益は年間平均-28.2%の割合で減少していますが、 Life Sciences業界の収益は年間 増加しています。収益は年間4.9% 26.1%割合で 増加しています。主要情報-28.17%収益成長率-23.79%EPS成長率Life Sciences 業界の成長26.83%収益成長率26.06%株主資本利益率-16.17%ネット・マージン-21.49%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • May 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €9.95m (up 49% from FY 2022). Net loss: €4.66m (loss widened 72% from FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.すべての更新を表示Recent updatesお知らせ • May 28Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026.Buy Or Sell Opportunity • Nov 11Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 1.7% to €1.75. The fair value is estimated to be €1.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 122% over the last year. Earnings per share has declined by 102%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 58% per annum over the same time period.New Risk • Nov 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€404k net loss in 3 years). Market cap is less than US$100m (€58.4m market cap, or US$67.3m).Breakeven Date Change • Sep 11Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 14Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Breakeven Date Change • Jun 20Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.New Risk • Jun 05New major risk - Revenue and earnings growthEarnings have declined by 7.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€58.4m market cap, or US$66.8m).お知らせ • Jun 04Pangaea Oncology, S.A., Annual General Meeting, Jul 07, 2025Pangaea Oncology, S.A., Annual General Meeting, Jul 07, 2025.New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€502k net loss in 2 years). Market cap is less than US$100m (€59.4m market cap, or US$66.3m).Breakeven Date Change • Apr 24No longer forecast to breakevenThe analyst covering Pangaea Oncology no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €800.0k in 2024. New forecast suggests the company will make a loss of €800.0k in 2025.Breakeven Date Change • Dec 31No longer forecast to breakevenThe analyst covering Pangaea Oncology no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €800.0k in 2024. New forecast suggests the company will make a loss of €800.0k in 2025.New Risk • Sep 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€200k net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (€59.3m market cap, or US$65.4m).お知らせ • Jun 05Pangaea Oncology, S.A., Annual General Meeting, Jul 02, 2024Pangaea Oncology, S.A., Annual General Meeting, Jul 02, 2024.Reported Earnings • May 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €9.95m (up 49% from FY 2022). Net loss: €4.66m (loss widened 72% from FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.分析記事 • Nov 09Is Pangaea Oncology (BME:PANG) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Nov 03New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €2.7m Forecast net loss in 1 year: €600k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€600k net loss next year). Market cap is less than US$100m (€58.5m market cap, or US$62.8m).Breakeven Date Change • Nov 03Forecast to breakeven in 2024The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests losses will reduce by 78% to 2023. The company is expected to make a profit of €900.0k in 2024. Average annual earnings growth of 99% is required to achieve expected profit on schedule.New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.0% average weekly change). Market cap is less than US$100m (€58.5m market cap, or US$62.1m).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Breakeven Date Change • Apr 01Forecast to breakeven in 2022The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests the company will make a profit of €800.0k in 2022. Average annual earnings growth of 111% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 23Forecast to breakeven in 2022The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests the company will make a profit of €800.0k in 2022. Average annual earnings growth of 91% is required to achieve expected profit on schedule.分析記事 • May 17Pangaea Oncology, S.A.'s (BME:PANG) About To Shift From Loss To ProfitWe feel now is a pretty good time to analyse Pangaea Oncology, S.A.'s ( BME:PANG ) business as it appears the company...Is New 90 Day High Low • Feb 11New 90-day low: €1.42The company is down 12% from its price of €1.62 on 13 November 2020. The Spanish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 10.0% over the same period.分析記事 • Feb 01Analysts Expect Pangaea Oncology, S.A. (BME:PANG) To Breakeven SoonWe feel now is a pretty good time to analyse Pangaea Oncology, S.A.'s ( BME:PANG ) business as it appears the company...Is New 90 Day High Low • Jan 07New 90-day low: €1.44The company is down 3.0% from its price of €1.49 on 09 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 3.0% over the same period.お知らせ • Oct 15Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL for €1.5 million.Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL for €1.5 million on October 13, 2020. Under the terms of transaction, Vidaro Inversiones purchased a total of 1.11 million securities of Pangaea Oncology at price of €1.36 for each Pangea share. Vidaro Inversiones S.L. completed the acquisition of 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL on October 13, 2020.Is New 90 Day High Low • Oct 14New 90-day high: €1.54The company is up 3.0% from its price of €1.49 on 16 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 14% over the same period.収支内訳Pangaea Oncology の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BME:PANG 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 2517-415031 Dec 2417-114030 Jun 2414-513031 Mar 2412-511031 Dec 2310-59030 Sep 238-47030 Jun 236-36031 Mar 237-36031 Dec 227-35030 Sep 227-25030 Jun 227-25031 Mar 227-15031 Dec 217-14030 Sep 217-14030 Jun 217-14031 Mar 216-14031 Dec 206-24030 Sep 206-34030 Jun 206-44031 Mar 206-44031 Dec 196-54030 Sep 196-34030 Jun 195-24031 Mar 196-14031 Dec 186-14030 Sep 186-24030 Jun 186-24031 Mar 186-24031 Dec 176-24030 Sep 176-14030 Jun 175-14031 Mar 175-14031 Dec 165-14030 Sep 165-14030 Jun 16503031 Mar 16403031 Dec 154030質の高い収益: PANGは現在利益が出ていません。利益率の向上: PANGは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PANGは利益が出ておらず、過去 5 年間で損失は年間28.2%の割合で増加しています。成長の加速: PANGの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: PANGは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 5.4% ) と比較することは困難です。株主資本利益率高いROE: PANGは現在利益が出ていないため、自己資本利益率 ( -16.17% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/26 20:20終値2026/06/26 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pangaea Oncology, S.A. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Alfredo Echevarria OteguiLighthouse-IEAF Servicios de Analisis
Reported Earnings • May 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €9.95m (up 49% from FY 2022). Net loss: €4.66m (loss widened 72% from FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • May 28Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026Pangaea Oncology, S.A., Annual General Meeting, Jun 29, 2026.
Buy Or Sell Opportunity • Nov 11Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 1.7% to €1.75. The fair value is estimated to be €1.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 122% over the last year. Earnings per share has declined by 102%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 58% per annum over the same time period.
New Risk • Nov 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€404k net loss in 3 years). Market cap is less than US$100m (€58.4m market cap, or US$67.3m).
Breakeven Date Change • Sep 11Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 14Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Breakeven Date Change • Jun 20Forecast breakeven date pushed back to 2027The analyst covering Pangaea Oncology previously expected the company to break even in 2025. New forecast suggests the company will make a profit of €100.0k in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
New Risk • Jun 05New major risk - Revenue and earnings growthEarnings have declined by 7.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€58.4m market cap, or US$66.8m).
お知らせ • Jun 04Pangaea Oncology, S.A., Annual General Meeting, Jul 07, 2025Pangaea Oncology, S.A., Annual General Meeting, Jul 07, 2025.
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€502k net loss in 2 years). Market cap is less than US$100m (€59.4m market cap, or US$66.3m).
Breakeven Date Change • Apr 24No longer forecast to breakevenThe analyst covering Pangaea Oncology no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €800.0k in 2024. New forecast suggests the company will make a loss of €800.0k in 2025.
Breakeven Date Change • Dec 31No longer forecast to breakevenThe analyst covering Pangaea Oncology no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €800.0k in 2024. New forecast suggests the company will make a loss of €800.0k in 2025.
New Risk • Sep 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€200k net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (€59.3m market cap, or US$65.4m).
お知らせ • Jun 05Pangaea Oncology, S.A., Annual General Meeting, Jul 02, 2024Pangaea Oncology, S.A., Annual General Meeting, Jul 02, 2024.
Reported Earnings • May 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €9.95m (up 49% from FY 2022). Net loss: €4.66m (loss widened 72% from FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
分析記事 • Nov 09Is Pangaea Oncology (BME:PANG) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Nov 03New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €2.7m Forecast net loss in 1 year: €600k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€600k net loss next year). Market cap is less than US$100m (€58.5m market cap, or US$62.8m).
Breakeven Date Change • Nov 03Forecast to breakeven in 2024The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests losses will reduce by 78% to 2023. The company is expected to make a profit of €900.0k in 2024. Average annual earnings growth of 99% is required to achieve expected profit on schedule.
New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.0% average weekly change). Market cap is less than US$100m (€58.5m market cap, or US$62.1m).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Breakeven Date Change • Apr 01Forecast to breakeven in 2022The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests the company will make a profit of €800.0k in 2022. Average annual earnings growth of 111% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The analyst covering Pangaea Oncology expects the company to break even for the first time. New forecast suggests the company will make a profit of €800.0k in 2022. Average annual earnings growth of 91% is required to achieve expected profit on schedule.
分析記事 • May 17Pangaea Oncology, S.A.'s (BME:PANG) About To Shift From Loss To ProfitWe feel now is a pretty good time to analyse Pangaea Oncology, S.A.'s ( BME:PANG ) business as it appears the company...
Is New 90 Day High Low • Feb 11New 90-day low: €1.42The company is down 12% from its price of €1.62 on 13 November 2020. The Spanish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 10.0% over the same period.
分析記事 • Feb 01Analysts Expect Pangaea Oncology, S.A. (BME:PANG) To Breakeven SoonWe feel now is a pretty good time to analyse Pangaea Oncology, S.A.'s ( BME:PANG ) business as it appears the company...
Is New 90 Day High Low • Jan 07New 90-day low: €1.44The company is down 3.0% from its price of €1.49 on 09 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 3.0% over the same period.
お知らせ • Oct 15Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL for €1.5 million.Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL for €1.5 million on October 13, 2020. Under the terms of transaction, Vidaro Inversiones purchased a total of 1.11 million securities of Pangaea Oncology at price of €1.36 for each Pangea share. Vidaro Inversiones S.L. completed the acquisition of 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL on October 13, 2020.
Is New 90 Day High Low • Oct 14New 90-day high: €1.54The company is up 3.0% from its price of €1.49 on 16 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 14% over the same period.